D A Morrow

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 31:1460-5. 1998
  2. ncbi request reprint Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial
    David A Morrow
    Cardiovascular Division and TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 40:71-7. 2002
  3. ncbi request reprint A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy
    D A Morrow
    TIMI Trials Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 358:1571-5. 2001
  4. ncbi request reprint Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3
    D A Morrow
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 286:1356-9. 2001
  5. ncbi request reprint Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy
    D A Morrow
    Department of Medicine and Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 36:1812-7. 2000
  6. ncbi request reprint TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 102:2031-7. 2000
  7. ncbi request reprint Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Chem 46:453-60. 2000
  8. ncbi request reprint Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 35:358-62. 2000
  9. ncbi request reprint Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram
    J A de Lemos
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 140:373-8. 2000
  10. ncbi request reprint Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy
    J A de Lemos
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Clin Chim Acta 298:85-97. 2000

Collaborators

Detail Information

Publications75

  1. ncbi request reprint C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 31:1460-5. 1998
    ....
  2. ncbi request reprint Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial
    David A Morrow
    Cardiovascular Division and TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 40:71-7. 2002
    ....
  3. ncbi request reprint A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy
    D A Morrow
    TIMI Trials Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 358:1571-5. 2001
    ..Available models for predicting mortality in STEMI include up to 45 variables, but have consistently shown advanced age, increased heart rate, and decreased blood pressure to be among the strongest predictors...
  4. ncbi request reprint Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3
    D A Morrow
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 286:1356-9. 2001
    ..Developed and validated in multiple clinical trials of fibrinolysis, the risk score has not been validated in a community-based population...
  5. ncbi request reprint Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy
    D A Morrow
    Department of Medicine and Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 36:1812-7. 2000
    ....
  6. ncbi request reprint TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 102:2031-7. 2000
    ..Complex multivariable models identify independent predictors and quantify their relative contribution to mortality risk but are too cumbersome to be readily applied in clinical practice...
  7. ncbi request reprint Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Chem 46:453-60. 2000
    ..Until adequate cTnI standardization is possible, an evidence-based approach evaluating each assay at specific thresholds appears warranted...
  8. ncbi request reprint Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 35:358-62. 2000
    ....
  9. ncbi request reprint Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram
    J A de Lemos
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 140:373-8. 2000
    ..We evaluated the combination of a baseline myoglobin assay and early (60- to 90-minute) ST resolution for risk stratification after ST-segment elevation myocardial infarction...
  10. ncbi request reprint Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy
    J A de Lemos
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Clin Chim Acta 298:85-97. 2000
    ..Despite a favorable kinetic profile, however, H-FABP does not appear to represent a significant advance over myoglobin in the noninvasive detection of reperfusion after thrombolysis...
  11. ncbi request reprint The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes
    J A de Lemos
    Thrombolysis in Myocardial Infarction Study Group, Boston, USA
    N Engl J Med 345:1014-21. 2001
    ....
  12. ncbi request reprint Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial
    D A Morrow
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 286:2405-12. 2001
    ....
  13. ncbi request reprint An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur Heart J 23:223-9. 2002
    ..We evaluated the TIMI Risk Score for Unstable Angina and Non-ST Elevation Myocardial Infarction for predicting clinical outcomes and the efficacy of tirofiban in non-ST elevation acute coronary syndromes...
  14. ncbi request reprint Troponins in patients with acute coronary syndromes: biologic, diagnostic, and therapeutic implications
    D A Morrow
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cardiovasc Toxicol 1:105-10. 2001
    ....
  15. ncbi request reprint Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials)
    Shaheeda Ahmed
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, USA
    J Thromb Thrombolysis 21:119-29. 2006
    ..We aimed to quantify the outcomes of fibrinolysis and adjunctive antithrombin therapy for STEMI stratified by age...
  16. ncbi request reprint Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome
    Kausik K Ray
    Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, United Kingdom
    Circulation 115:3071-8. 2007
    ..Neopterin is a soluble marker of monocyte activation, and elevated levels are of prognostic value in patients with stable coronary artery disease...
  17. ncbi request reprint Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 115:2822-8. 2007
    ..The safety and efficacy of pharmacological reperfusion therapy in women with ST-elevation myocardial infarction are of particular interest...
  18. ncbi request reprint Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 99:344-8. 2007
    ..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication...
  19. ncbi request reprint Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22)
    Kausik K Ray
    Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 98:861-5. 2006
    ..In conclusion, in this large study of patients with ACS, we provide evidence that increased endothelial activation after ACS is independently associated with increased long-term risk of death, myocardial infarction, or recurrent ACS...
  20. ncbi request reprint Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PR
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 152:756-61. 2006
    ..A variety of imaging modalities have implicated impaired myocardial perfusion in the pathogenesis of acute coronary syndromes (ACSs)...
  21. ncbi request reprint Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes
    Michelle O'Donoghue
    Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Ave, First Floor, Boston, Mass 02115, USA
    Circulation 114:550-7. 2006
    ..Although it has been investigated as an early marker of acute myocardial infarction, its prognostic utility in acute coronary syndromes has not been established...
  22. ncbi request reprint The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:37-42. 2006
    ..This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis...
  23. ncbi request reprint Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy
    Jessica L Mega
    TIMI Thrombolysis in Myocardial Infarction Study Group, Boston, Massachusetts 12114, USA
    J Thromb Thrombolysis 22:71-6. 2006
    ..While statins have been shown to reduce cerebrovascular events (CVE), the relationship between cholesterol, C-reactive protein (CRP), and CVE in patients treated with different statin strategies is still being explored...
  24. ncbi request reprint A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:2364-73. 2006
    ....
  25. ncbi request reprint Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 47:2326-31. 2006
    ..We aimed to determine whether intensive statin therapy reduces hospitalization for heart failure (HF) in high-risk patients...
  26. ncbi request reprint Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction
    Elliott M Antman
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 354:1477-88. 2006
    ..Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardial infarction. We compared a low-molecular-weight heparin, enoxaparin, with unfractionated heparin for this purpose...
  27. ncbi request reprint Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial
    Satish Bhadriraju
    McLaren Regional Medical Center Michigan State University, Flint, Michigan, USA
    Am J Cardiol 97:1573-7. 2006
    ..Glucose levels during ACS may be an important addition to the risk stratification of patients with ACS and a potentially important target for therapy...
  28. ncbi request reprint Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 97:1473-7. 2006
    ..In conclusion, patients undergoing DES implantation achieved more reductions in periprocedural markers of inflammation and necrosis than patients receiving bare metal stents among those with non-ST-elevation acute coronary syndrome...
  29. ncbi request reprint Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 49:2238-46. 2007
    ....
  30. ncbi request reprint Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 49:2256-63. 2007
    ....
  31. doi request reprint Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:2422-9. 2008
    ..We sought to test the prognostic performance of thrombus precursor protein (TpP) in patients presenting with an acute coronary syndrome (ACS)...
  32. doi request reprint Antithrombotic therapy to support primary PCI
    David A Morrow
    N Engl J Med 358:2280-2. 2008
  33. doi request reprint Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 117:1936-44. 2008
    ....
  34. pmc Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18
    David A Morrow
    TIMI Study Group Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 29:1096-102. 2008
    ....
  35. ncbi request reprint Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes
    Robert W Yeh
    Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    Am J Cardiol 100:1734-8. 2007
    ..In conclusion, thrombocytopenia is a significant correlate of adverse events in patients presenting with non-ST-elevation ACS treated with either enoxaparin or UFH...
  36. pmc Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
    David A Morrow
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 155:49-55. 2008
    ..Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome...
  37. ncbi request reprint Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
    David A Morrow
    Department of Medicine, Harvard Medical School, Boston, MA, USA
    Am Heart J 154:1078-84, 1084.e1. 2007
    ..Potent antithrombotic therapies may offer particular benefit for these high-risk patients and must be balanced against the potential for increased bleeding...
  38. ncbi request reprint TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction
    Christian T Ruff
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Am J Med 120:993-8. 2007
    ....
  39. ncbi request reprint Clinical application of C-reactive protein across the spectrum of acute coronary syndromes
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02461, USA
    Clin Chem 53:1800-7. 2007
    ..The ability to formulate recommendations regarding clinical use of hsCRP is limited by a paucity of data regarding several key issues. The purpose of this study was to evaluate hsCRP across the spectrum of ACS...
  40. ncbi request reprint A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2070-6. 2007
    ..To determine the relationship between a strategy of enoxaparin (ENOX), early ST-segment resolution (STRes), and clinical outcomes on patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolysis...
  41. ncbi request reprint Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2077-86. 2007
    ....
  42. ncbi request reprint Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial
    Benjamin A Steinberg
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 154:54-61. 2007
    ..We hypothesized that adjustment for baseline risk would minimize such variations...
  43. ncbi request reprint Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis
    Roberto R Giraldez
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    Eur Heart J 28:1566-73. 2007
    ..We compared outcomes of ST-elevation myocardial infarction (STEMI) patients randomized to a strategy of either enoxaparin or unfractionated heparin (UFH) to support fibrinolysis...
  44. doi request reprint Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
    ..In conclusion, compared with patients with ACS without previous CABG, those with previous CABG have a higher risk for adverse cardiac events and may derive similar benefit from intensive statin therapy...
  45. ncbi request reprint Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
    Michelle O'Donoghue
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1745-52. 2006
    ..The prognostic value of Lp-PLA2 in patients with acute coronary syndromes (ACS) has not been established...
  46. ncbi request reprint Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies
    James L Januzzi
    Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Am Heart J 151:360-6. 2006
    ..Troponin testing is useful for evaluating patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS); however, a significant percentage of patients are troponin negative at presentation and develop late rise of the marker...
  47. ncbi request reprint Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:580-6. 2004
    ..We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI)...
  48. ncbi request reprint Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 109:874-80. 2004
    ..We sought to examine the effect of these advances on clinical outcomes and the benefits of an early invasive strategy in UA/NSTEMI...
  49. ncbi request reprint C-reactive protein, inflammation, and coronary risk
    Paul M Ridker
    Center for Cardiovascular Disease in Women, Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Cardiol Clin 21:315-25. 2003
    ..Ongoing and future investigation will clarify the specific pathophysiologic relationships through which these markers correlate with adverse prognosis...
  50. ncbi request reprint Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality
    C Michael Gibson
    TIMI Study Chairman s Office, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    J Am Coll Cardiol 42:1535-43. 2003
    ..We hypothesized that impaired renal function would also be associated with poorer clinical outcomes among patients with ST-segment elevation myocardial infarction (STEMI) treated with fibrinolysis...
  51. ncbi request reprint Soluble CD40L: risk prediction after acute coronary syndromes
    Nerea Varo
    Donald W Reynolds Cardiovascular Clinical Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 108:1049-52. 2003
    ..This study tested the hypothesis that plasma sCD40L, alone or in combination with troponin (cTnI) or C-reactive protein (CRP), may identify patients with acute coronary syndromes at heightened risk for recurrent cardiac events...
  52. ncbi request reprint Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy
    David A Morrow
    Circulation 108:250-2. 2003
  53. ncbi request reprint Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18
    David A Morrow
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:1264-72. 2003
    ....
  54. ncbi request reprint Assessing the success of fibrinolysis: can we let the interventionalist rest?
    David A Morrow
    Am Heart J 145:380-2. 2003
  55. ncbi request reprint Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservati
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Am Coll Cardiol 40:1761-8. 2002
    ....
  56. ncbi request reprint Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration
    Howard A Cooper
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 144:790-5. 2002
    ..The sum of ST-segment resolution (sum-STRES) has a high positive predictive value (PPV) for a patent IRA, but is quite time-consuming...
  57. ncbi request reprint The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies
    James A de Lemos
    Thrombolysis in Myocardial Infarction TIMI Study Group, Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, TX 75390 9047, USA
    J Am Coll Cardiol 40:238-44. 2002
    ..The goal of this study was to define the prognostic value of serum myoglobin in patients with non-ST-elevation acute coronary syndromes (ACS)...
  58. ncbi request reprint Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction
    Graham C Wong
    Department of Medicine, Brigham and Women s Hospital, Boston, Mass, USA
    Circulation 106:202-7. 2002
    ..Other pathophysiological mechanisms underlying troponin elevation remain unclear...
  59. ncbi request reprint Identification of patients at high risk for death and cardiac ischemic events after hospital discharge
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 143:966-70. 2002
    ..Patients with unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) remain at risk for death and cardiac ischemic events after being discharged from the hospital...
  60. ncbi request reprint Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  61. ncbi request reprint Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction
    Masahisa Shimpo
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 109:2186-90. 2004
    ..Serum levels of ST2 are associated with prognosis in nonischemic heart failure, but the predictive value of ST2 in patients with acute myocardial infarction is unknown...
  62. ncbi request reprint Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Circulation 112:3846-54. 2005
    ..Whether these advantages translate into greater infarct-related artery patency and fewer adverse clinical events in patients with ST-elevation myocardial infarction (STEMI) receiving fibrinolytic therapy remains under study...
  63. ncbi request reprint Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial
    Kausik K Ray
    Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:1417-24. 2005
    ..This study sought to evaluate what set of factors correlate with higher or lower C-reactive protein (CRP) levels in patients receiving standard and intensive statin therapy...
  64. ncbi request reprint Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:1411-6. 2005
    ..This study sought to evaluate the safety and efficacy of achieving very low calculated low-density lipoprotein (LDL) levels with intensive statin therapy...
  65. ncbi request reprint Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms
    Jessica L Mega
    TIMI Study Group, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 149:846-50. 2005
    ....
  66. ncbi request reprint Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 45:1644-8. 2005
    ..The aim of this research was to compare relative efficacy of different statin regimens in achieving the dual goals of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) reduction...
  67. ncbi request reprint Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thro
    Elliott M Antman
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:217-26. 2005
  68. ncbi request reprint Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy
    Kausik K Ray
    TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA, USA
    Eur Heart J 26:440-6. 2005
    ....
  69. ncbi request reprint Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction
    Dimitrios Karmpaliotis
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 94:1113-7. 2004
    ..High TRS at presentation is associated with abnormal myocardial perfusion, even after adjusting for possible confounders...
  70. ncbi request reprint Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction
    Saihari Sadanandan
    Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA
    J Am Coll Cardiol 44:564-8. 2004
    ..We hypothesized that elevated B-type natriuretic peptide (BNP) levels would be associated with a greater severity of angiographic disease and a greater extent of myocardium at risk...
  71. ncbi request reprint B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy
    Jessica L Mega
    TIMI Study Group, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 44:335-9. 2004
    ....
  72. ncbi request reprint Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Clin Chim Acta 346:119-28. 2004
    ..Future research is needed to identify therapies of particular benefit for patients with ACS and natriuretic peptide elevation...
  73. ncbi request reprint Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18
    John V Wylie
    Division of Cardiology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Mass 02215, USA
    Am Heart J 148:173-80. 2004
    ..We developed and validated a risk score to predict which patients will develop CHF...
  74. ncbi request reprint Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Am J Cardiol 93:1362-7, A5-6. 2004
    ..This new end point is proposed to evaluate the success of reperfusion therapy in patients who undergo early angiography...
  75. ncbi request reprint Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 105:1760-3. 2002
    ..Little is known, however, about the utility of these biomarkers in combination...